Previous 10 |
home / stock / knbwf / knbwf news
Early indications show that Kyowa Kirin has a blockbuster drug with KHK4083, a treatment for severe atopic dermatitis (eczema). Phase 2 trials have shown encouraging results and the agreement to jointly develop and commercialize the drug with Amgen is a positive signal. With both ...
The Beer Tax Unification Act will damage Kirin's competitive pricing in the beer-substitute market for the medium to long term. Kirin's 53.8% stake in pharmaceutical company Kyowa Kirin causes problems over parent attributable net income and free cash flow disclosure. The shares a...
Kirin management has done a commendable job with the domestic brewing business, particularly on product development, but the Japanese market doesn't offer much growth. Management is pivoting hard toward nutritional and "wellness" products, and looking to leverage a large investment in...